Lipocine Inc. (LPCN): PT Lowered News

LPCN – H.C. Wainwright & Co. cuts PT to $3 from $10. This new price target represents a 60.43% upside over the stock’s previous closing price of $1.87.


Update: As of Jan. 17, 2018, this bearish analyst call has returned -21.39%.


Key Facts Surrounding This News Item


  • LPCN had a POWR Rating of D (Sell) coming into today.
  • LPCN was -42.27% below its 10-Day Moving Average coming into today.
  • LPCN was -44.32% below its 20-Day Moving Average coming into today.
  • LPCN was -46.57% below its 50-Day Moving Average coming into today.
  • LPCN was -49.75% below its 100-Day Moving Average coming into today.
  • LPCN was -51.91% below its 200-Day Moving Average coming into today.
  • LPCN had returned -45.64% year-to-date leading up to today’s news, versus a +3.47% return from the benchmark S&P 500 during the same period.

More Info About Lipocine Inc. (LPCN)


Lipocine develops pharmaceutical products using its oral drug delivery technology in the areas of men’s and women’s health, with a current focus being testosterone replacement. The company was founded in 1997 and is based in Salt Lake City, Utah. View our full LPCN ticker page with ratings, news, and more.

Try StockNews.com Premium Today!


Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

LPCN at a Glance

LPCN Current POWR Rating™
Overall POWR Rating™
LPCN Current Price $1.47 3.29%
More LPCN Ratings, Data, and News

LPCN Price Reaction

The day of this event (Jan. 12, 2018)
LPCN Closing Price$1.71 8.56%
LPCN Volume1,579,500
460.27% from avg
Leading up to this event
LPCN 1-mo return46.65%
After this event
LPCN 1-day return23.03%

LPCN Price Chart



More Lipocine Inc. (LPCN) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All LPCN News
Page generated in 0.966 seconds.